Cargando…

Circulating immune profile can predict survival of metastatic uveal melanoma patients: results of an exploratory study

Metastatic uveal melanoma (UM) is a poor prognosis malignancy. Immunotherapy is commonly employed, despite the low activity, considering the lack of other effective systemic treatments. In this study, the prognostic and predictive role of soluble immune checkpoints and inflammatory cytokines/chemoki...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rossi, Ernesto, Zizzari, Ilaria Grazia, Di Filippo, Alessandra, Acampora, Anna, Pagliara, Monica Maria, Sammarco, Maria Grazia, Simmaco, Maurizio, Lionetto, Luana, Botticelli, Andrea, Bria, Emilio, Marchetti, Paolo, Blasi, Maria Antonietta, Tortora, Giampaolo, Schinzari, Giovanni, Nuti, Marianna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Melanoma Immunotherapy SF – Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9302506/ https://www.ncbi.nlm.nih.gov/pubmed/35258435 http://dx.doi.org/10.1080/21645515.2022.2034377

Ejemplares similares

Immunotherapy and radiotherapy in melanoma: a multidisciplinary comprehensive review
por: Tagliaferri, Luca, et al.
Publicado: (2021)

Immunological Backbone of Uveal Melanoma: Is There a Rationale for Immunotherapy?
por: Rossi, Ernesto, et al.
Publicado: (2019)

Combination of immunotherapy and other targeted therapies in advanced cutaneous melanoma
por: Marconcini, Riccardo, et al.
Publicado: (2021)

Pembrolizumab as first-line treatment for metastatic uveal melanoma
por: Rossi, Ernesto, et al.
Publicado: (2019)

Intratumoral therapies and in-situ vaccination for melanoma
por: Huppert, Laura A., et al.
Publicado: (2022)

Editorial of special focus on melanoma immunotherapy
por: Rossi, Ernesto
Publicado: (2022)

Neoadjuvant immune checkpoint inhibitors in high-risk stage III melanoma
por: Ferraresi, Virginia, et al.
Publicado: (2021)

Predictive factors of neoadjuvant immune checkpoint blockade in melanoma
por: Sarver, Melissa, et al.
Publicado: (2021)

Hepatic Radiotherapy in Addition to Anti-PD-1 for the Treatment of Metastatic Uveal Melanoma Patients
por: Rossi, Ernesto, et al.
Publicado: (2023)

Role of gut microbiome on immunotherapy efficacy in melanoma
por: Bibbò, Stefano, et al.
Publicado: (2021)

Immune checkpoint inhibitors in adjuvant setting after radical resection of melanoma: a meta-analysis of the pivotal trials
por: Bersanelli, Melissa, et al.
Publicado: (2021)

Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma
por: Rossi, Ernesto, et al.
Publicado: (2019)

Radiomics to predict immunotherapy efficacy in advanced renal cell carcinoma: A retrospective study
por: Rossi, Ernesto, et al.
Publicado: (2023)

“Skin rashes” and immunotherapy in melanoma: distinct dermatologic adverse events and implications for therapeutic management
por: Sollena, Pietro, et al.
Publicado: (2021)

Clinical and ultrasonographic features of choroidal metastases based on primary cancer site: Long-term experience in a single center
por: Blasi, Maria Antonietta, et al.
Publicado: (2021)

Conjunctival Melanoma: Genetic and Epigenetic Insights of a Distinct Type of Melanoma
por: Rossi, Ernesto, et al.
Publicado: (2019)

Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
por: Botticelli, Andrea, et al.
Publicado: (2018)

Baseline Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios as Biomarkers of Survival in Cutaneous Melanoma: A Multicenter Cohort Study
por: Wade, Ryckie G., et al.
Publicado: (2018)

Radiological and clinical findings in uveal melanoma treated by plaque interventional radiotherapy (brachytherapy): Visual atlas and literature review on response assessment
por: Fionda, Bruno, et al.
Publicado: (2022)

Tryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1
por: Botticelli, Andrea, et al.
Publicado: (2020)

How Should We View the Results of the Multicenter Selective Lymphadenectomy Trial-1 (MSLT-1)?
por: Ross, Merrick I., et al.
Publicado: (2008)

Isolated Tumor Cells and Long-Term Prognosis of Patients with Melanoma
por: van Akkooi, A. C. J., et al.
Publicado: (2008)

Sorting Through the Heterogeneity of Recurrent Melanoma
por: Jacobs, Lisa K., et al.
Publicado: (2008)

Cutaneous Melanoma and Sentinel Lymph Node Biopsy
por: van Akkooi, A. C. J., et al.
Publicado: (2008)

Detection of Melanoma Nodal Metastases; Differences in Detection Between Elderly and Younger Patients Do Not Affect Survival
por: Kruijff, S., et al.
Publicado: (2010)

Therapeutic Surgical Management of Palpable Melanoma Groin Metastases: Superficial or Combined Superficial and Deep Groin Lymph Node Dissection
por: van der Ploeg, A. P. T., et al.
Publicado: (2011)

Quality of Life After Axillary or Groin Sentinel Lymph Node Biopsy, With or Without Completion Lymph Node Dissection, in Patients With Cutaneous Melanoma
por: de Vries, Mattijs, et al.
Publicado: (2009)

Nonsentinel Node Metastases in Melanoma: Do They Reflect the Biology of the Tumor, the Lymph Node or the Surgeon?: Editorial to Accompany Ghaferi et al., ASO-2009-03-0312.R1
por: Sondak, Vernon K.
Publicado: (2009)

Why Does No One Want to Perform Lymph Node Dissection Anymore?
por: McMasters, Kelly M.
Publicado: (2009)

Potential Cost-Effectiveness of US-Guided FNAC in Melanoma Patients as a Primary Procedure and in Follow-Up
por: van Akkooi, Alexander C. J., et al.
Publicado: (2009)

Who Is to Blame for False-Negative Sentinel Node Biopsies in Melanoma?
por: Sondak, Vernon K., et al.
Publicado: (2009)

False-Negative Sentinel Node Biopsy
por: Nieweg, Omgo E.
Publicado: (2009)

Outcome After Therapeutic Lymph Node Dissection in Patients with Unknown Primary Melanoma Site
por: Prens, Sebastiaan P., et al.
Publicado: (2011)

Use of S-100B to Evaluate Therapy Effects during Bevacizumab Induction Treatment in AJCC Stage III Melanoma
por: Kruijff, S., et al.
Publicado: (2011)

20 Years Experience of TNF-Based Isolated Limb Perfusion for In-Transit Melanoma Metastases: TNF Dose Matters
por: Deroose, Jan P., et al.
Publicado: (2011)

S-100B Concentrations Predict Disease-Free Survival in Stage III Melanoma Patients
por: Kruijff, S., et al.
Publicado: (2009)

Survival and the Sentinel Lymph Node in Melanoma
por: Faries, Mark
Publicado: (2009)

Multimarker Reverse Transcriptase-Polymerase Chain Reaction Assay in Lymphatic Drainage and Sentinel Node Tumor Burden
por: Rutkowski, Piotr, et al.
Publicado: (2010)

Combined Analysis of Phase III Trials Evaluating [(99m)Tc]Tilmanocept and Vital Blue Dye for Identification of Sentinel Lymph Nodes in Clinically Node-Negative Cutaneous Melanoma
por: Sondak, Vernon K., et al.
Publicado: (2012)

Individualized Surgery: Gamma-Probe-Guided Lymphadenectomy in Patients with Clinically Enlarged Lymph Node Metastases from Melanomas
por: Kretschmer, Lutz, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_49pva04u89537a0vbcnngtr7d3